Advertisement
New Zealand markets closed

  • NZX 50

    11,699.79
    -28.27 (-0.24%)
     

  • NZD/USD

    0.6136
    +0.0015 (+0.24%)
     

  • NZD/EUR

    0.5637
    +0.0008 (+0.15%)
     

  • ALL ORDS

    8,082.30
    -67.80 (-0.83%)
     

  • ASX 200

    7,814.40
    -66.90 (-0.85%)
     

  • OIL

    80.00
    +0.77 (+0.97%)
     

  • GOLD

    2,419.80
    +34.30 (+1.44%)
     

  • NASDAQ

    18,546.23
    -11.73 (-0.06%)
     

  • FTSE

    8,420.26
    -18.39 (-0.22%)
     

  • Dow Jones

    40,003.59
    +134.21 (+0.34%)
     

  • DAX

    18,704.42
    -34.39 (-0.18%)
     

  • Hang Seng

    19,553.61
    +177.08 (+0.91%)
     

  • NIKKEI 225

    38,787.38
    -132.88 (-0.34%)
     

  • NZD/JPY

    95.4860
    +0.4250 (+0.45%)
     

Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024

PR Newswire
·2-min read

-- Conference Call Scheduled for Wednesday, May 8, 2024, at 8:00 a.m. ET --

NEWTON, Mass., May 2, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report first quarter 2024 financial results on Wednesday, May 8, 2024. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Wednesday, May 8, 2024, to discuss the financial results and other company updates.

(PRNewsfoto/Karyopharm Therapeutics Inc.)
(PRNewsfoto/Karyopharm Therapeutics Inc.)

To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company's website approximately two hours after the event.

ADVERTISEMENT

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-report-first-quarter-2024-financial-results-on-may-8-2024-302135120.html

SOURCE Karyopharm Therapeutics Inc.